Format

Send to

Choose Destination
Nat Commun. 2018 Mar 15;9(1):1092. doi: 10.1038/s41467-018-03301-0.

Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.

Author information

1
Department of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, CH-1066, Switzerland.
2
Ovarian Cancer Research Center, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
3
Swiss Institute of Bioinformatics, Lausanne, CH-1015, Switzerland.
4
Department of Medicine, Division of Immunology and Allergy, Lausanne University Hospital, Lausanne, CH-1066, Switzerland.
5
Urology Research Unit, Lausanne University Hospital, Lausanne, CH-1011, Switzerland.
6
Department of Pathology and Laboratory Medicine, Immunogenetics Laboratory, The Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.
7
Department of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, CH-1066, Switzerland. george.coukos@chuv.ch.
8
Department of Oncology, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, CH-1066, Switzerland. alexandre.harari@chuv.ch.

Abstract

Immunotherapy directed against private tumor neo-antigens derived from non-synonymous somatic mutations is a promising strategy of personalized cancer immunotherapy. However, feasibility in low mutational load tumor types remains unknown. Comprehensive and deep analysis of circulating and tumor-infiltrating lymphocytes (TILs) for neo-epitope specific CD8+ T cells has allowed prompt identification of oligoclonal and polyfunctional such cells from most immunotherapy-naive patients with advanced epithelial ovarian cancer studied. Neo-epitope recognition is discordant between circulating T cells and TILs, and is more likely to be found among TILs, which display higher functional avidity and unique TCRs with higher predicted affinity than their blood counterparts. Our results imply that identification of neo-epitope specific CD8+ T cells is achievable even in tumors with relatively low number of somatic mutations, and neo-epitope validation in TILs extends opportunities for mutanome-based personalized immunotherapies to such tumors.

PMID:
29545564
PMCID:
PMC5854609
DOI:
10.1038/s41467-018-03301-0
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center